Healthcare ❯ Pharmaceuticals ❯ Drug Pricing ❯ Medicaid

Patient Access

White House Pauses Drug Tariffs as Pfizer Signs On to TrumpRx and MFN Pricing

Health policy analysts caution the announced steps may deliver budget savings more than lower pharmacy bills for typical patients.

White House Clinches Pfizer Pricing Deal Tied to Tariff Reprieve and $70 Billion U.S. Investment